OBJECTIVE: To examine whether patients with no insurance or Medicaid are more likely to present with advanced-stage laryngeal cancer. DESIGN: Retrospective cohort study from the National Cancer Database, 1996-2003. SETTING: Hospital-based practice. PARTICIPANTS: Patients with known insurance status diagnosed as having invasive laryngeal cancer at Commission on Cancer facilities (N = 61 131) were included. Adjusted and unadjusted logistic regression models analyzed the likelihood of presenting at a more advanced stage. MAIN OUTCOME MEASURES: Overall stage of laryngeal cancer (early vs advanced) and tumor size (T stage) at diagnosis. RESULTS: Patients with advanced-stage laryngeal cancer at diagnosis were more likely to be uninsured (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.79-2.15) or covered by Medicaid (OR, 2.40; 95% CI, 2.21-2.61) compared with those with private insurance. Similarly, patients were most likely to present with the largest tumors (T4 disease) if they were uninsured (OR, 2.92; 95% CI, 2.60-3.28) or covered by Medicaid (OR, 3.97; 95% CI, 3.56-4.34). Patients who were black, between ages 18 and 56 years, and who resided in zip codes with low proportions of high school graduates or low median household incomes were also more likely to be diagnosed as having advanced disease and/or larger tumors. CONCLUSIONS: Individuals lacking insurance or having Medicaid are at greatest risk for presenting with advanced laryngeal cancer. Results for the Medicaid group may be influenced by the postdiagnosis enrollment of uninsured patients. It is important to consider the impact of insurance coverage on stage at diagnosis and associated morbidity, mortality, quality of life, and costs.
OBJECTIVE: To examine whether patients with no insurance or Medicaid are more likely to present with advanced-stage laryngeal cancer. DESIGN: Retrospective cohort study from the National Cancer Database, 1996-2003. SETTING: Hospital-based practice. PARTICIPANTS: Patients with known insurance status diagnosed as having invasive laryngeal cancer at Commission on Cancer facilities (N = 61 131) were included. Adjusted and unadjusted logistic regression models analyzed the likelihood of presenting at a more advanced stage. MAIN OUTCOME MEASURES: Overall stage of laryngeal cancer (early vs advanced) and tumor size (T stage) at diagnosis. RESULTS:Patients with advanced-stage laryngeal cancer at diagnosis were more likely to be uninsured (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.79-2.15) or covered by Medicaid (OR, 2.40; 95% CI, 2.21-2.61) compared with those with private insurance. Similarly, patients were most likely to present with the largest tumors (T4 disease) if they were uninsured (OR, 2.92; 95% CI, 2.60-3.28) or covered by Medicaid (OR, 3.97; 95% CI, 3.56-4.34). Patients who were black, between ages 18 and 56 years, and who resided in zip codes with low proportions of high school graduates or low median household incomes were also more likely to be diagnosed as having advanced disease and/or larger tumors. CONCLUSIONS: Individuals lacking insurance or having Medicaid are at greatest risk for presenting with advanced laryngeal cancer. Results for the Medicaid group may be influenced by the postdiagnosis enrollment of uninsured patients. It is important to consider the impact of insurance coverage on stage at diagnosis and associated morbidity, mortality, quality of life, and costs.
Authors: Michael T Halpern; Melissa A Romaire; Susan G Haber; Florence K Tangka; Susan A Sabatino; David H Howard Journal: Cancer Date: 2014-08-25 Impact factor: 6.860
Authors: Ya-Chen Tina Shih; Patricia A Ganz; Denise Aberle; Amy Abernethy; Justin Bekelman; Otis Brawley; James S Goodwin; Jim C Hu; Deborah Schrag; Jennifer S Temel; Lowell Schnipper Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Josena K Stephen; Kang Mei Chen; Veena Shah; Shaleta Havard; Mei Lu; Vanessa P Schweitzer; Glendon Gardner; Maria J Worsham Journal: Otolaryngol Head Neck Surg Date: 2012-01-20 Impact factor: 3.497
Authors: Arash O Naghavi; Michelle I Echevarria; G Daniel Grass; Tobin J Strom; Yazan A Abuodeh; Kamran A Ahmed; Youngchul Kim; Andy M Trotti; Louis B Harrison; Kosj Yamoah; Jimmy J Caudell Journal: Cancer Date: 2016-08-01 Impact factor: 6.860
Authors: Rittal Mehta; Kota Sahara; Katiuscha Merath; J Madison Hyer; Diamantis I Tsilimigras; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Mary Dillhoff; Allan Tsung; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2019-06-13 Impact factor: 3.452
Authors: Gary V Walker; Stephen R Grant; B Ashleigh Guadagnolo; Karen E Hoffman; Benjamin D Smith; Matthew Koshy; Pamela K Allen; Usama Mahmood Journal: J Clin Oncol Date: 2014-08-04 Impact factor: 44.544
Authors: Joseph Kwok; Scott M Langevin; Athanassios Argiris; Jennifer R Grandis; William E Gooding; Emanuela Taioli Journal: Cancer Date: 2010-01-15 Impact factor: 6.860
Authors: Scott M Langevin; Dominique S Michaud; Melissa Eliot; Edward S Peters; Michael D McClean; Karl T Kelsey Journal: Cancer Causes Control Date: 2012-09-08 Impact factor: 2.506